Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

Published byIrene Mora Segura Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic."— Presentation transcript:

1 Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs
Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic drugs. Binding of VEGFR2 results in intracellular phosphorylation and activation of multiple downstream pathways, including PLCγ, MAPK, PI3K, AKT, and SRC. Proangiogenic signals and VEGFR activity are modulated by several receptors, including integrins, FGFR, PDGFR, Notch, and TIE2. Activation of VEGFR1 leads to downstream effects on haematopoietic stem cells (HSCs), dendritic cell (DC) maturation, and chemotaxis, whereas VEGFR3 signalling promotes lymphangiogenesis. General drug targets are illustrated for aflibercept, bevacizumab, ramucirumab, and multiple receptor tyrosine kinase inhibitors. Adapted with permission © Clarke, J. M. & Hurwitz, H. I. Expert Opin. Biol. Ther. 13, 1187–1196 (2013)123. Adapted with permission © Clarke, J. M. & Hurwitz, H. I. Expert Opin. Biol. Ther. 13, 1187–1196 (2013) Lordick, F. & Janjigian, Y. Y. (2016) Clinical impact of tumour biology in the management of gastroesophageal cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic."

Similar presentations

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology www.bowelcancerwest.org.uk.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Trans. Vis. Sci. Tech ;5(2):10. doi: /tvst Figure Legend:

Trans. Vis. Sci. Tech ;5(2):10. doi: /tvst Figure Legend:
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Figure 4 The mechanistic link between the epithelial-to-mesenchymal
Miriam Marqués, Francisco X. Real  European Urology 

Miriam Marqués, Francisco X. Real  European Urology 
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 1 Current treatments for PNETs

Figure 1 Current treatments for PNETs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 3 The cell cycle and the role of CDK4/6 inhibition
Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 4 Possible combination therapies CDK4/6 inhibitors
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.
Figure 1 CAR-T-cell design

Figure 1 CAR-T-cell design

Similar presentations

Ads by Google